Silver Book Fact

Resolvins, a family of lipid mediators, have shown potential in resolving persistent inflammatory pain.

Xu Z, Zhang L, Liu T, Park J, et al. Resolvins RvE1 and RvD1 Attenuate Inflammatory Pain Via Central and Peripheral Actions. Nature Med. 2010; 16(5): 592-7. http://www.nature.com/nm/journal/v16/n5/full/nm.2123.html

Reference

Title
Resolvins RvE1 and RvD1 Attenuate Inflammatory Pain Via Central and Peripheral Actions
Publication
Nature Med
Publication Date
2010
Authors
Xu Z, Zhang L, Liu T, Park J, et al
Volume & Issue
Volume 16, Issue 5
Pages
592-7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Targeting A-type K+ channels in primary sensory neurons could provide a novel mechanism-based therapy for the treatment of bone cancer pain–one of the most severe types of chronic pain.  
  • 60% of people with persistent back pain who turned to complementary and alternative medicine perceived a “”great deal”” of benefit.  
  • Antiepileptic drugs relieve persistent neuropathic pain. One meta-analysis found gabapentin to be associated with moderate benefit (equivalent to 30% pain relief) in close to 1 in 2 patients, and…  
  • Understanding the role of genetics in pain mechanisms is increasing and the potential now exists to conduct genome-wide screens in model organisms to look for pain-associated genes.  
  • A meta-analysis of duloxetine, an anti-depressant, found a 50% reduction in pain at 12 weeks for diabetic peripheral neuropathy, and a 50% reduction in pain at 12 weeks for fibromyalgia.